COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers28/10/2025
-   
  Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines28/10/2025
-   
  Présentation du tout premier grand modèle de langage multiomique au monde au salon Global Health Exhibition de Riyad, ou la promesse d’un décodage du langage de la biologie humaine28/10/2025
-   
  Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 202528/10/2025
-   
  Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome28/10/2025
-   
  Communiqué de presse : Sanofi place 3 milliards de dollars d’emprunts obligataires28/10/2025
-   
  Press release: Sanofi successfully prices USD 3 billion of bond issue28/10/2025
-   
  Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance28/10/2025
-   
  Outset Medical to Report Third Quarter 2025 Financial Results on Monday, November 10, 202527/10/2025
-   
  IRADIMED CORPORATION to Hold Third Quarter of 2025 Financial Results Conference Call on November 3, 202527/10/2025
-   
  Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 202527/10/2025
-   
  Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 202527/10/2025
-   
  MEDIA ADVISORY: Patients join Day of Action at Ontario Legislature to demand action on complaints about private clinics’ charges27/10/2025
-   
  BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant27/10/2025
-   
  Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 202527/10/2025
-   
  Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process27/10/2025
-   
  Amwell® to report third quarter 2025 operating results; company leaders to attend upcoming investor conferences27/10/2025
-   
  Elixir Medical annonce de nouveaux résultats cliniques significatifs pour le DynamX® Bioadaptor, démontrant une réduction de près de 50 % des taux d’événements coronariens par rapport à la norme actuelle de soins ICP27/10/2025
-   
  Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard of Care27/10/2025
Pages